Lipum AB (publ) (STO: LIPUM)

Sweden flag Sweden · Delayed Price · Currency is SEK
16.30
+0.60 (3.82%)
Nov 19, 2024, 4:41 PM CET
87.36%
Market Cap 358.49M
Revenue (ttm) 53.00K
Net Income (ttm) -39.24M
Shares Out 21.21M
EPS (ttm) -2.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,065
Open 15.90
Previous Close 15.70
Day's Range 15.80 - 17.60
52-Week Range 5.50 - 17.60
Beta 0.20
Analysts n/a
Price Target n/a
Earnings Date Oct 25, 2024

About Lipum AB

Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-sti... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol LIPUM
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.